https://www.businesswire.com/news/home/20260715942620/en/Mercks-LIPFENDRA-enlicitide-is-the-First-and-Only-Once-Daily-Oral-PCSK9-Inhibitor-Approved-by-the-U.S.-

https://www.businesswire.com/news/home/20260715942620/en/Mercks-LIPFENDRA-enlicitide-is-the-First-and-Only-Once-Daily-Oral-PCSK9-Inhibitor-Approved-by-the-U.S.-FDA-to-Reduce-LDL-C-in-Adults-with-Hypercholesterolemia https://www.businesswire.com/news/home/20260715942620/en/Mer...